Literature DB >> 23394804

Serum placental growth factor as a predictor of early onset preeclampsia in overweight/obese pregnant women.

Sanjib Kumar Ghosh1, Shashi Raheja, Anita Tuli, Chitra Raghunandan, Sneh Agarwal.   

Abstract

The purpose of this study was to analyze whether maternal serum placental growth factor (PlGF) could predict early onset preeclampsia (<32 weeks of gestation) in overweight/obese pregnant women, and whether it could do it more effectively than in normal/underweight pregnant women. A prospective cohort study was conducted on 1678 pregnant women with singleton pregnancies, who were grouped as underweight, normal, overweight, and obese on the basis of body mass index, followed by serum PlGF estimation at 20 to 22 weeks of gestation. A cut-off value of <144 pg/mL for PlGF was determined by Receiver Operating Characteristic curve analysis to identify risk of early onset preeclampsia. Univariate logistic regression analysis revealed significantly stronger association between PlGF <144 pg/mL and early onset preeclampsia in overweight/obese pregnant women (odds ratio 7.64; 95% confidence interval 5.34-10.12; P = .000) than in normal/underweight pregnant women (odds ratio 2.95; 95% confidence interval 1.74-4.26; P = .007). Weight and PlGF levels in study women had a significant negative correlation (r = 0.663; P = .002). Serum PlGF in early second trimester could be an effective predictor of early onset preeclampsia in overweight/obese pregnant women and may be more effective than in normal/underweight pregnant women.
Copyright © 2013 American Society of Hypertension. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23394804     DOI: 10.1016/j.jash.2012.12.006

Source DB:  PubMed          Journal:  J Am Soc Hypertens        ISSN: 1878-7436


  9 in total

Review 1.  Metabolic abnormalities and obesity's impact on the risk for developing preeclampsia.

Authors:  Frank T Spradley
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2016-11-30       Impact factor: 3.619

Review 2.  Increased risk for the development of preeclampsia in obese pregnancies: weighing in on the mechanisms.

Authors:  Frank T Spradley; Ana C Palei; Joey P Granger
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-10-07       Impact factor: 3.619

3.  Administration of recombinant human placental growth factor decreases blood pressure in obese hypertensive pregnant rats.

Authors:  Ana C Palei; Adelene Y Tan; Woo S Joo; Paul Kussie; Christopher D Anderson; Barbara A Wilson; Frank T Spradley
Journal:  J Hypertens       Date:  2020-11       Impact factor: 4.776

4.  Assessment of preeclampsia risk by use of serum ionized magnesium-based equation.

Authors:  Chatchai Kreepala; Maethaphan Kitporntheranunt; Worrawat Sangwipasnapaporn; Warit Rungsrithananon; Krittanont Wattanavaekin
Journal:  Ren Fail       Date:  2018-11       Impact factor: 2.606

5.  Serum biomarkers combined with uterine artery Doppler in prediction of preeclampsia.

Authors:  Lijie Li; Yanmei Zheng; Ying Zhu; Jianchun Li
Journal:  Exp Ther Med       Date:  2016-08-29       Impact factor: 2.447

6.  Evaluation of sFlt-1/PlGF Ratio for Predicting and Improving Clinical Management of Pre-eclampsia: Experience in a Specialized Perinatal Care Center.

Authors:  Hélène Caillon; Cécile Tardif; Erwan Dumontet; Norbert Winer; Damien Masson
Journal:  Ann Lab Med       Date:  2018-03       Impact factor: 3.464

7.  Serum and urine vitamin D metabolite analysis in early preeclampsia.

Authors:  J A Tamblyn; C Jenkinson; D P Larner; M Hewison; M D Kilby
Journal:  Endocr Connect       Date:  2017-12-07       Impact factor: 3.335

Review 8.  What are the metabolic precursors which increase the risk of pre-eclampsia and how could these be investigated further.

Authors:  Jenny E Myers
Journal:  Placenta       Date:  2017-08-24       Impact factor: 3.481

9.  High-fat diet from parental generation exaggerates body and adipose tissue weights in pregnant offspring.

Authors:  Frank T Spradley
Journal:  PLoS One       Date:  2020-08-20       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.